Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Lean Rx vs REMEVi

Lean Rx
Graded #319

Lower grade

vs+9.800000000000004
REMEVi
Graded #108

Higher grade

The verdict

REMEVi takes it — 70.4/100 to 60.6/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueREMEVi +14
40
54
Dose & formulationLean Rx +11
75
64
Clinical oversightREMEVi +5
81
86
Labs & monitoringREMEVi +13
52
65
FulfillmentREMEVi +37
60
97
Contract termsREMEVi +14
55
69
Lean Rx · left barREMEVi · right bar

The numbers

MetricLean RxREMEVi
WeighScore60.6/10070.4/100
GradeCC
Scorecard rank#319#108
Semaglutide$266/mo (starting dose, compounded)$199/mo (starting dose, compounded)
Tirzepatide$399/mo (starting dose, compounded)$269/mo (starting dose, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Lean Rx

Graded #319 · C

Strengths

  • Both semaglutide and tirzepatide offered
  • Three formulations: injectable, sublingual, and tablet
  • Upfront pricing with no hidden fees advertised
  • Semaglutide starts at a low $266/month
  • Telehealth call with a licensed provider before prescribing

Where it loses points

  • Compounded-only; no FDA-approved branded options
  • No published state availability list
  • Platform is technology only, not a healthcare provider itself
  • Provider credentials not detailed on site
REMEVi

Graded #108 · C

Strengths

  • The first bilingual GLP-1 clinic — care delivered in English and Spanish by clinicians trained in both, not auto-translated
  • Compounded semaglutide from $199/mo and tirzepatide from $269/mo on the 52-week plan, with the same price every month (no titration price hikes)
  • LegitScript-certified and licensed in all 50 states + DC, with an NPI-verified pharmacy and overnight shipping
  • Transparent all-inclusive pricing with no hidden fees and cancel anytime; full legal suite (Privacy, Terms, HIPAA, Refund)

Where it loses points

  • Lowest pricing requires a 52-week commitment — month-to-month is higher ($279 semaglutide / $339 tirzepatide)
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy or Zepbound
  • The specific compounding pharmacy is not named (described as 'NPI-verified')
  • A newer, patient-founded clinic; press mentions (Fortune, AP, Reuters) are syndicated PR, not editorial endorsements

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard